Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients

Clinica Terapeutica

Volumn 159, Issue 6, 2008, Pages 449-452

  Vici, P ^a   Viola, G ^a   Botti, C ^a   Rossi, S ^b   Vitucci, C ^a   Corsetti, S ^a   Di Lauro, L ^a   Sergi, D ^a   Foggi, P ^a   Perri, P ^a   Tirelli, C ^c   Mottolese, M ^a   Fattoruso, S I S ^a   Lopez, M ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Dipartimento Medico Sanofi Aventis   (Italy)

^c NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

Author keywords

Breast cancer; Docetaxel; HER2 positive; Taxanes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II; EPIRUBICIN; FEMALE; GENES, ERBB-2; HEART DISEASES; HUMANS; MULTICENTER STUDIES AS TOPIC; NEOPLASM PROTEINS; PACLITAXEL; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 58849094563     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Singer CF, Köstler WJ, Hudelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies. Biochim Biophys Acta 2008; Mar 4
2. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-84
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-72
4. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29-36
5. Seidman A, Hudis C, Pierri MK, et al. Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience. J Clin Oncol 2002;20:1215-21
6. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Center experience. J Clin Oncol 2006; 24:4107-15
7. Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open.label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004,96:739-49
8. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carbo- platin and trastuzumab in Her2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005; 94:S5(suppl 1)
9. nd Interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res Treat 2006 (abstr 52)
10. Jones SE, Savin MA, Holmes FA et al. Phase HJ trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006; 24:5381-7
11. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354:809-20
12. Viani GA, Afonso SL, Stefano EJ, et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007; 7:153
13. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26:1231-8
14. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23:7811-9
15. Smith I, Procter M, Gelber R, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29-36
16. Guarneri V, Frassoldati A, Bruzzi P, et al. Multicentric, ranomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2-positive breast cancer (Short-HER trial; NCT00629278). Clin Breast Cancer 2008; 8:453-6
17. Spielmann M, Rochè H, Humbler Y et al. 3-year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients : results of the PACS-04 trial. Breast Cancer Res Treat 2007; 106:72
18. Pegram M, Forbes J, Pienkowski T et al. BCIRG 007: First overall survival analysis of randomized phase III trial trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC), J Clin Oncol 2007; 25:968S
19. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24:2786-92